DC-806 + itraconazole

DC-806 + itraconazole is a combination therapy consisting of **DC-806**, an orally available small molecule antagonist of **interleukin-17 (IL-17)**, and **itraconazole**, a triazole antifungal drug. DC-806 acts as a direct inhibitor of the pro-inflammatory cytokine IL-17, which plays a central role in the pathogenesis of psoriasis and other immunological disorders. It was developed for oral administration with the intention of matching the efficacy of biologics targeting IL-17, but in a small molecule format. Itraconazole, meanwhile, inhibits fungal cytochrome P450-dependent enzyme 14α-demethylase, disrupting ergosterol synthesis and cell membrane formation in fungi; it is approved for use in various fungal infections. The rationale for combining DC-806 with itraconazole may be to address co-existing fungal infections in immunosuppressed patients or to evaluate drug-drug interactions, as itraconazole can affect metabolism of some small molecules.